奥马珠单抗对重度日本杉树花粉症患者有酬和无酬工作生产力的影响

数据集获取（Figshare）

• 源站标题：The impact of omalizumab on paid and unpaid work productivity among severe Japanese cedar pollinosis (JCP) patients
• DOI：10.6084/m9.figshare.19003251.v2
• 发布日期：2022-02-09
• 文件数：5 个
• 文件总体积：86.39 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/The_impact_of_omalizumab_on_paid_and_unpaid_work_productivity_among_severe_Japanese_cedar_pollinosis_JCP_patients/19003251

命令行下载

curl -L -o "ijme_a_2033051_sm9612.docx" "https://ndownloader.figshare.com/files/34018669"
curl -L -o "ijme_a_2033051_sm5550.docx" "https://ndownloader.figshare.com/files/33820785"
curl -L -o "ijme_a_2033051_sm5548.docx" "https://ndownloader.figshare.com/files/33820788"
curl -L -o "ijme_a_2033051_sm5536.docx" "https://ndownloader.figshare.com/files/33820791"
curl -L -o "ijme_a_2033051_sm5482.docx" "https://ndownloader.figshare.com/files/33820797"

文件清单

• ijme_a_2033051_sm9612.docx（26.39 KB）
• ijme_a_2033051_sm5550.docx（14.12 KB）
• ijme_a_2033051_sm5548.docx（14.28 KB）
• ijme_a_2033051_sm5536.docx（17.22 KB）
• ijme_a_2033051_sm5482.docx（14.38 KB）

文件总体积 86.39 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Japanese cedar pollinosis (JCP) is a form of seasonal allergic rhinitis that affects 38.8% of the Japanese population. Particularly severe and most severe symptoms among JCP patients can lead to impairments of paid work productivity and unpaid work activities. Indeed, the current standard of care (SoC) is not always able to relieve these symptoms. Omalizumab, a novel JCP treatment recently approved in Japan, provides an effective add-on therapy to the SoC. This study estimates the effect of omalizumab on paid and unpaid work activities (i.e. its social impact) in patients with severe and most severe JCP symptoms in Japan.
The impact of omalizumab was estimated through a one-year static cohort model using the Work Productivity and Activity Impairment Allergy Specific (WPAI-AS) questionnaire derived from a clinical trial on omalizumab enrolling patients with severe and most severe JCP symptoms, which had been conducted in Japan. This effect was quantified using Japanese official statistics on employment and time use. The human capital approach and the proxy good approach were employed to monetize paid and unpaid work activities, respectively. A sensitivity analysis was implemented to account for modeling structural uncertainties.
Our results show that the use of omalizumab might reduce the paid and unpaid work productivity losses due to severe and most severe JCP by nearly one-third. In the severe symptom period of three weeks, 36.6 million hours of lost paid and unpaid work hours could be avoided, which sums up to a monetized productivity loss of 728.3 million USD.
Omalizumab could provide substantial benefits in terms of paid and unpaid work activities in patients with severe and most severe JCP. Our results also highlight the importance of considering unpaid work in estimating productivity costs due to poor health.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.19003251.v2（source: https://tandf.figshare.com/articles/dataset/The_impact_of_omalizumab_on_paid_and_unpaid_work_productivity_among_severe_Japanese_cedar_pollinosis_JCP_patients/19003251）。